Your browser doesn't support javascript.
loading
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
Abuhadra, Nour; Sun, Ryan; Bassett, Roland L; Huo, Lei; Chang, Jeffrey T; Teshome, Mediget; Clayborn, Alyson R; White, Jason B; Ravenberg, Elizabeth E; Adrada, Beatriz E; Candelaria, Rosalind P; Yang, Wei; Ding, Qingqing; Symmans, W Fraser; Arun, Banu; Damodaran, Senthil; Koenig, Kimberly B; Layman, Rachel M; Lim, Bora; Litton, Jennifer K; Thompson, Alastair; Ueno, Naoto T; Piwnica-Worms, Helen; Hortobagyi, Gabriel N; Valero, Vicente; Tripathy, Debu; Rauch, Gaiane M; Moulder, Stacy; Yam, Clinton.
Affiliation
  • Abuhadra N; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Sun R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bassett RL; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Huo L; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chang JT; Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Teshome M; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Clayborn AR; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • White JB; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Ravenberg EE; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Adrada BE; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Candelaria RP; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yang W; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ding Q; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Symmans WF; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Arun B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Damodaran S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Koenig KB; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Layman RM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Lim B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Thompson A; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ueno NT; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Piwnica-Worms H; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Valero V; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • Rauch GM; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Moulder S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. moulder_stacy@lilly.com.
  • Yam C; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. cyam@mdanderson.org.
Invest New Drugs ; 41(3): 391-401, 2023 Jun.
Article in En | MEDLINE | ID: mdl-37043123
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Triple Negative Breast Neoplasms Limits: Female / Humans Language: En Journal: Invest New Drugs Year: 2023 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Triple Negative Breast Neoplasms Limits: Female / Humans Language: En Journal: Invest New Drugs Year: 2023 Document type: Article Affiliation country: